Second- and third-generation ALK inhibitors for non-small cell lung cancer

Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Savooji, John, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782349/
https://www.ncbi.nlm.nih.gov/pubmed/26951079
http://dx.doi.org/10.1186/s13045-016-0251-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782349/
https://www.ncbi.nlm.nih.gov/pubmed/26951079
http://dx.doi.org/10.1186/s13045-016-0251-8

Ejemplares similares